ßTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells.
Biochem Biophys Res Commun
; 682: 27-38, 2023 11 19.
Article
de En
| MEDLINE
| ID: mdl-37801987
ABSTRACT
The solute carrier family 35 F2 (SLC35F2) belongs to membrane-bound carrier proteins that are associated with multiple cancers. The main factor that determines cancer progression is the expression level of SLC35F2. Thus, identifying the E3 ligase that controls SLC35F2 protein abundance in cancer cells is critical. Here, we identified ßTrCP1 interacting with and reducing the SLC35F2 protein level. ßTrCP1 signals SLC35F2 protein ubiquitination and reduces SLC35F2 protein half-life. The mRNA expression pattern between ßTrCP1 and SLC35F2 across a panel of cancer cell lines showed a negative correlation. Additionally, the depletion of ßTrCP1 accumulated SLC35F2 protein and promoted SLC35F2-mediated cell growth, migration, invasion, and colony formation ability in HeLa cells. Overall, we demonstrate that ßTrCP1 acts as a tumor suppressor by controlling SLC35F2 protein abundance in cancer cells. The depletion of ßTrCP1 promotes SLC35F2-mediated carcinogenesis. Thus, we envision that ßTrCP1 may be a potential target for cancer therapeutics.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Ubiquitin-protein ligases
/
Tumeurs
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
En
Journal:
Biochem Biophys Res Commun
Année:
2023
Type de document:
Article
Pays d'affiliation:
Corée du Sud